Cleave Biosciences Receives Orphan Designation from FDA for CB-5083 for Treatment of Multiple Myeloma Cleave Biosciences Receives Orphan Designation from FDA for CB-5083 for Treatment of Multiple Myeloma admin2019-07-25T13:29:04-07:00July 13th, 2015|
